These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38824414)

  • 41. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.
    Albain KS; Unger JM; Crowley JJ; Coltman CA; Hershman DL
    J Natl Cancer Inst; 2009 Jul; 101(14):984-92. PubMed ID: 19584328
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials.
    Sherry AD; Lin TA; McCaw ZR; Beck EJ; Kouzy R; Abi Jaoude J; Passy AH; Miller AM; Kupferman GS; Fuller CD; Thomas CR; Koay EJ; Tang C; Msaouel P; Ludmir EB
    Int J Cancer; 2024 Aug; ():. PubMed ID: 39138841
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies.
    Sivendran S; Newport K; Horst M; Albert A; Galsky MD
    Trials; 2015 Aug; 16():341. PubMed ID: 26253548
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sample Size Calculation in Oncology Trials: Quality of Reporting and Implications for Clinical Cancer Research.
    Bariani GM; de Celis Ferrari AC; Precivale M; Arai R; Saad ED; Riechelmann RP
    Am J Clin Oncol; 2015 Dec; 38(6):570-4. PubMed ID: 24401665
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reporting of loss to follow-up information in randomised controlled trials with time-to-event outcomes: a literature survey.
    Vervölgyi E; Kromp M; Skipka G; Bender R; Kaiser T
    BMC Med Res Methodol; 2011 Sep; 11():130. PubMed ID: 21936924
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of COVID-19 Outbreak through Telemedicine Implementation on Data Reporting During Oncology Clinical Trials.
    Bouleftour W; Daguenet E; Tinquaut F; Magne N
    Cancer Invest; 2021 Jan; 39(1):15-20. PubMed ID: 33258396
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Heart Failure with Preserved Ejection Fraction Trials Have Heterogeneous Control Groups: a Comparison of Kaplan-Meier Curves.
    Luo H; Zhang C; Wang J; Zhu J; Jia X
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):577-580. PubMed ID: 30187346
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group.
    Kumar A; Soares H; Wells R; Clarke M; Hozo I; Bleyer A; Reaman G; Chalmers I; Djulbegovic B;
    BMJ; 2005 Dec; 331(7528):1295. PubMed ID: 16299015
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review.
    Mohyuddin GR; Koehn K; Abdallah AO; W Sborov D; Rajkumar SV; Kumar S; McClune B
    Am J Hematol; 2021 Jun; 96(6):690-697. PubMed ID: 33735453
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potential surrogate endpoints for overall survival in locoregionally advanced nasopharyngeal carcinoma: an analysis of a phase III randomized trial.
    Chen YP; Chen Y; Zhang WN; Liang SB; Zong JF; Chen L; Mao YP; Tang LL; Li WF; Liu X; Guo Y; Lin AH; Liu MZ; Sun Y; Ma J
    Sci Rep; 2015 Jul; 5():12502. PubMed ID: 26219568
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Processes to activate phase III clinical trials in a cooperative oncology group: the elephant is monstrous.
    Steensma DP
    J Clin Oncol; 2007 Mar; 25(9):1148; author reply 1148-9. PubMed ID: 17369584
    [No Abstract]   [Full Text] [Related]  

  • 52. American Society of Clinical Oncology Annual Meeting highlights.
    Printz C
    Cancer; 2014 Oct; 120(20):3099. PubMed ID: 25283526
    [No Abstract]   [Full Text] [Related]  

  • 53. Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group.
    Aplenc R; Fisher BT; Huang YS; Li Y; Alonzo TA; Gerbing RB; Hall M; Bertoch D; Keren R; Seif AE; Sung L; Adamson PC; Gamis A
    Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2(Suppl 2):37-43. PubMed ID: 22552978
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Validating Restricted Mean Survival Time Estimates From Reconstructed Kaplan-Meier Data Against Original Trial Individual Patient Data From Trials Conducted by the Canadian Cancer Trials Group.
    Everest L; Blommaert S; Tu D; Pater JL; Hay A; Cheung MC; Chan KKW
    Value Health; 2022 Jul; 25(7):1157-1164. PubMed ID: 35779942
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.
    Ji Y; Jin JY; Hyman DM; Kim G; Suri A
    Clin Transl Sci; 2018 Jul; 11(4):345-351. PubMed ID: 29392871
    [No Abstract]   [Full Text] [Related]  

  • 56. Oncology trial abstracts showed suboptimal improvement in reporting: a comparative before-and-after evaluation using CONSORT for Abstract guidelines.
    Ghimire S; Kyung E; Lee H; Kim E
    J Clin Epidemiol; 2014 Jun; 67(6):658-66. PubMed ID: 24439069
    [TBL] [Abstract][Full Text] [Related]  

  • 57. When are "positive" clinical trials in oncology truly positive?
    Ocana A; Tannock IF
    J Natl Cancer Inst; 2011 Jan; 103(1):16-20. PubMed ID: 21131576
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials.
    Lesan V; Olivier T; Prasad V
    Eur J Cancer; 2024 May; 202():114022. PubMed ID: 38547775
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcome switching in randomized controlled oncology trials reporting on surrogate endpoints: a cross-sectional analysis.
    Falk Delgado A; Falk Delgado A
    Sci Rep; 2017 Aug; 7(1):9206. PubMed ID: 28835682
    [TBL] [Abstract][Full Text] [Related]  

  • 60. How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials.
    Sofeu CL; Rondeau V
    PLoS One; 2020; 15(1):e0228098. PubMed ID: 31990928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.